McDonough takes the helm at T2:
This article was originally published in Clinica
President of Cytyc's business development subsidiary John McDonough has taken on the new role of CEO of T2 Biosystems, a Cambridge, Massachusetts-based start up developing portable diagnostic systems that combine nanotechnology with miniaturised MRI technology. Previously at Cytyc Development Corporation, Mr McDonough was responsible for corporate strategy, acquisitions and venture investments. In his new role, the CEO said he aims to help T2 achieve its objectives for 2008, which includes producing a prototype instrument and identifying and advancing multiple diagnostic tests to the preclinical stage of development.
You may also be interested in...
Teligent has achieved a “pivotal step in our journey toward securing a strong financial future,” according to management, after recapitalizing its significant debt burden and gaining access to more cash.
Pfizer has entered into an agreement with Premier to supply five essential medications to US healthcare providers through Premier’s ProvideGx program. Both companies aim to secure supply of products specifically used by COVID patients.
Announcing his “first step to take on pricing of generic drugs,” billionaire Mark Cuban recently associated his name with a new US generics company “to show that capitalism can be compassionate.” In an exclusive chat with Generics Bulletin, the newly established company’s CEO Alex Oshmyansky revealed that they started working on the company “in stealth” since 2018.